COCP - コクリスタル・ファ―マ (Cocrystal Pharma Inc.) コクリスタル・ファ―マ

 COCPのチャート


 COCPの企業情報

symbol COCP
会社名 Cocrystal Pharma Inc (コクリスタル・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Cocrystal Pharma Inc. is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.   コクリスタル・ファ―マは米国の医薬品企業。主にヒトのウィルス性疾患の治療薬の開発に従事する。ウィルスの複製機能を阻害する抗ウィルス治療薬で、RNAポリメラ―ゼ酵素、ヘリカ―ゼ酵素、C型肝炎のNS5Aたんぱく質、インフルエンザウィルスやノロウィルスのRNAポリメラ―ゼを含む。同社は薬物レベルでの酵素相互作用に焦点を当てる。本社はジョ―ジア州タッカ―。   Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
本社所在地 1860 Montreal Road Tucker GA 30084 USA
代表者氏名 Raymond F. Schinazi レイモンドF.シナジー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 425-398-7178
設立年月日 39052
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 10人
url https://www.cocrystalpharma.com/
nasdaq_url https://www.nasdaq.com/symbol/cocp
adr_tso
EBITDA EBITDA(百万ドル) -8.06300
終値(lastsale) 2.725
時価総額(marketcap) 81540382.1
時価総額 時価総額(百万ドル) 81.98923
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 75.14823
当期純利益 当期純利益(百万ドル) 0.04100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cocrystal Pharma Inc revenues was not reported. Net loss decreased 18% to $2.9M. Lower net loss reflects Research and development decrease of 40% to $2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.11.

 COCPのテクニカル分析


 COCPのニュース

   Sabby Management, Llc Buys Cocrystal Pharma Inc, Enochian BioSciences Inc, Aterian Inc, Sells ...  2021/08/18 16:38:36 GuruFocus
Related Stocks: ATOS , RIOT , MOGO , IONS , AMRN , HMCO , COCP , ENOB , ATER , RCON , VINC , GLBS , PENN , VTSI , 5UQ , XELA , XBI , AUPH ,
   Stock with Negative, Positive Change: Li Auto Inc. (NASDAQ:LI), Cocrystal Pharma, Inc. (NASDAQ:COCP)  2021/08/17 21:19:24 Stock Equity
Li Auto Inc. (NASDAQ:LI) with the stream of 0.47% also noticed, India Cocrystal Pharma, Inc. (NASDAQ:COCP) encountered a rapid change of -2.97% in the last hour of Tuesdays trading session. The post Stock with Negative, Positive Change: Li Auto Inc. (NASDAQ:LI), Cocrystal Pharma, Inc. (NASDAQ:COCP) appeared first on Stocks Equity .
   Stock Buzzers: Cocrystal Pharma, Inc. (NASDAQ:COCP), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)  2021/08/17 01:19:45 Stock Equity
Cocrystal Pharma, Inc. (COCP) with the stream of -4.73% also noticed, India AcelRx Pharmaceuticals, Inc. (ACRX) encountered a rapid change of -4.27% in the last hour of Mondays trading session. The post Stock Buzzers: Cocrystal Pharma, Inc. (NASDAQ:COCP), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) appeared first on Stocks Equity .
   Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates  2021/08/16 12:00:00 Cocrystal Pharma
   Attention Seeking Stock: Itau Unibanco Holding S.A. (NYSE:ITUB), Cocrystal Pharma, Inc. (NASDAQ:COCP)  2021/08/12 00:35:57 Stock Equity
Itau Unibanco Holding S.A. (NYSE:ITUB) with the stream of 0.43% also noticed, India Cocrystal Pharma, Inc. (NASDAQ:COCP) encountered a rapid change of 0.94% in the last hour of Wednesdays trading The post Attention Seeking Stock: Itau Unibanco Holding S.A. (NYSE:ITUB), Cocrystal Pharma, Inc. (NASDAQ:COCP) appeared first on Stocks Equity .
   Cocrystal Pharma added to Russell Microcap Index  2021/06/28 13:28:10 Seeking Alpha
   Cocrystal Joins Russell Microcap® Index  2021/06/28 12:00:00 Intrado Digital Media
BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that it will be added to the Russell Microcap ® Index after the U.S. market opens today, June 28, 2021.
   Cocrystal Joins Russell Microcap Index  2021/06/28 12:00:00 Wallstreet:Online
BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that it will be added to the Russell Microcap Index after
   Cocrystal Pharma plans to initiate a phase 1 trial of CC-42344 in Q3 2021  2021/06/23 12:13:41 Seeking Alpha
   Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter  2021/06/23 12:00:00 Intrado Digital Media
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in the third quarter of 2021.

 関連キーワード  (医薬品 米国株 コクリスタル・ファ―マ COCP Cocrystal Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)